Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.03% | 61.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.78% | 19.26% | |||
| Operating Income | 4.78% | -19.26% | |||
| Income Before Tax | 10.17% | -25.69% | |||
| Income Tax Expenses | 55.56% | -- | |||
| Earnings from Continuing Operations | 10.16% | -25.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -79.91% | -51.25% | |||
| Net Income | 9.94% | -26.34% | |||
| EBIT | 4.78% | -19.26% | |||
| EBITDA | 52.14% | -137.27% | |||
| EPS Basic | 52.25% | -159.77% | |||
| Normalized Basic EPS | 10.04% | -26.69% | |||
| EPS Diluted | 53.12% | -164.57% | |||
| Normalized Diluted EPS | 10.04% | -26.69% | |||
| Average Basic Shares Outstanding | 0.13% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||